Table S1. Treatment specific costs

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug/resource** | **Brand** | **Pack contents** | **Pack price (EUR)** | **Source** |
| IDegLira | Xultophy® | 900 IU/32.4 mg | 119.29 | Taxe April 2016 |
| Insulin glargine | Lantus® | 1,500 IU | 51.65 | Taxe April 2016 |
| Insulin aspart | NovoRapid® | 1,500 IU | 37.35 | Taxe April 2016 |
| Metformin | Non-proprietary | 90 tablets, 500mg/tablet | 1.23 | Taxe February 2016 |
| Needles | NovoFine 6mm/31G | 100 needles | 17.94 | Taxe February 2016 |
| Needles | UniFine Pentips 6mm/31G | 100 needles | 13.50 | Taxe February 2016 |
| SMBG test strips | Aviva Accu-check | 10 strips | 10.83 | Taxe February 2016 |
| SMBG lancets | One Touch ultra soft | 10 lancets | 0.94 | Taxe February 2016 |

Abbreviations: IU, international units; SMBG, self-monitored blood glucose. Pack price is PPP excluding 6% VAT: The pack price of IDegLira represents the target price.

Table S2. Management costs

|  |  |  |
| --- | --- | --- |
| **Management costs** | **Annual cost (EUR)** | **Notes** |
| Aspirin | 28.67 | Based on aspirin 100mg, 30 tablet pack |
| Statins | 8.77 | Based on simvastatin 40 mg, 30 tablet pack |
| ACE inhibitors | 9.37 | Based on losartan 50 mg, 30 tablet pack |
| Microalbuminuria screening | 4.59 | Laboratory urinalysis |
| Gross proteinuria screening | 4.59 | Laboratory urinalysis |
| Stopping ACEs due to adverse events | 0 | Assumed |
| Screening for eye disease | 102.25 | Based on consultation with general practitioner |
| Screening for diabetic foot complications | 13.14 | Podiatrist visit |

Abbreviations: ACE, angiotensin-converting enzyme. EUR, 2015 Euros

Table S3. Costs associated with health states and events

| **Complication Costs** | **Cost (EUR)** | **Key source** |
| --- | --- | --- |
| **CVD complications** | | |
| Myocardial infarction, year of event | 6,341 | Soekhlal et al, 2013 (1) |
| Myocardial infarction, 2+ years | 1,026 | Soekhlal et al, 2013 (1) |
| Angina, year of onset | 2,505 | Soekhlal et al, 2013 (1) |
| Angina, 2+ years | 618 | Soekhlal et al, 2013 (1) |
| Congestive heart failure, year of onset | 5,479 | Stevanovic et al, 2014 (2) |
| Congestive heart failure, 2+ years | 954 | Stevanovic et al, 2014 (2) |
| Stroke, year of event | 24,142 | Buisman et al, 2015 (3) |
| Stroke, 2+ years | 1,968 | Buisman et al, 2015 (3) |
| Stroke, death within 30 days | 5,523 | Buisman et al, 2015 (3) |
| Peripheral vascular disease, year of onset | 11,334 | Opendisdata.nl Zorginstituut Nederland -www.medicijnkosten.nl |
| Peripheral vascular disease 2+ years | 44 | Zorginstituut Nederland - www.medicijnkosten.nl |
| **Renal Complications** | | |
| Hemodialysis, year of onset | 81,256 | DBC tariffs - http://www.opendisdata.nl/ |
| Hemodialysis, 2+ years | 81,256 | DBC tariffs - http://www.opendisdata.nl/ |
| Peritoneal dialysis, year of onset | 88,749 | DBC tariffs - http://www.opendisdata.nl/ |
| Peritoneal dialysis, 2+ years | 88,749 | DBC tariffs - http://www.opendisdata.nl/ |
| Renal transplant, 1st year | 49,602 | Cavallo et al, 2014 (4) |
| Renal transplant, 2+ years | 2,438 | Cavallo et al, 2014 (4) |
| **Acute events** | | |
| Severe hypoglycemia | 929 | Expert opinion |
| Non-severe hypoglycemia | 6 | Expert opinion |
| **Eye Disease** | | |
| Laser treatment | 548 | http://www.opendisdata.nl/ |
| Cataract operation | 1,423 | Heijink et al, 2013 (5) |
| Cataract operation, 2+ years | 228 | De Vries et al, 2010 (6) |
| Blindness, year of onset | 4,385 | Koberlein et al, 2013 (7); Lafuma et al, 2006 (8) |
| Blindness, 2+ years | 4,385 | Koberlein et al, 2013 (7); Lafuma et al, 2006 (8) |
| **Neuropathy, foot ulcer, amputation** | | |
| Neuropathy, year of onset | 158 | NHG. Richtlijn diabetische voet. 2006(9) |
| Neuropathy, 2+ years | 158 | NHG. Richtlijn diabetische voet. 2006 |
| Amputation, procedure | 12,738 | DBC tariffs - http://www.opendisdata.nl/ |
| Amputation, prosthesis | 6,306 | Prismant hospital statistics 2007 number of amputations by type |
| Gangrene treatment | 3,247 | Redekop et al, 2003 (10) |
| Infected foot ulcer | 2,493 | Redekop et al, 2003 (10) |
| Uninfected foot ulcer | 2,739 | Redekop et al, 2003 (10) |
| Healed ulcer | 158 | NHG. Richtlijn diabetische voet. 2006 |

Abbreviations: CVD, cardiovascular disease; EUR, 2015 Euros

**References**

1. Soekhlal RR, Burgers LT, Redekop WK, Tan SS. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J. 2013 May;21(5):230-5.

2. Stevanovic J, Denee L, Koenders JM, Postma MJ. Incidence description and costs of acute heart failure in the Netherlands. Value Health. 2014;17:A328.

3. Buisman LR, Tan SS, Nederkoorn PJ, Koudstaal PJ, Redekop WK. Hospital costs of ischemic stroke and TIA in the Netherlands. Neurology. 2015 Jun 2;84(22):2208-15.

4. Cavallo MC, Sepe V, Conte F, Abelli M, Ticozzelli E, Bottazzi A, et al. Cost-effectiveness of kidney transplantation from DCD in Italy. Transplant Proc. 2014 Dec;46(10):3289-96.

5. Heijink R, Mosca I, Westert G. Effects of regulated competition on key outcomes of care: cataract surgeries in the Netherlands. Health Policy. 2013 Nov;113(1-2):142-50.

6. De Vries NE, Laurendeau C, Lafuma A, Berdeaux G, Nuijts RM. Lifetime costs and effectiveness of ReSTOR compared with a monofocal IOL and Array-SA40 in the Netherlands. Eye (Lond). 2010 Apr;24(4):663-72.

7. Koberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471.

8. Lafuma A, Brezin A, Fagnani F, Mimaud V, Mesbah M, Berdeaux G. Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France. Eur J Health Econ. 2006 Sep;7(3):158-64.

9. Department of Health. NHS Reference costs 2011-12. Available at: <https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012>.

10. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003;21(16):1171-83.